{"symbol":"REGN","fiscalQuarter":"Q4-2010","reportDate":"2011-02-17","reportTime":"BMO","status":"reported","company":{"name":"Regeneron Pharmaceuticals, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/REGN/earnings/Q4-2010","postBrief":{"headline":"Regeneron Pharmaceuticals Misses on EPS, Stock Down 0.08%","keyNumbers":[{"metric":"EPS","actual":"$-0.17","expected":"N/A","surprise":"+47.20%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["Management expressed confidence in future product pipeline.","They noted ongoing investments in research and development.","There was an emphasis on long-term growth potential despite current losses."],"summary":"Overall, management conveyed a sense of cautious optimism regarding future prospects. They highlighted the importance of their ongoing projects and investments."},"guidanceChanges":{"summary":"No forward guidance was provided during the earnings call.","changes":[]},"whatItMeans":"Regeneron's earnings report shows a significant surprise in EPS, but the stock reacted slightly down by 0.08%. The lack of revenue data and no guidance may have contributed to investor caution. Management's focus on long-term growth and product development suggests they are positioning for future success despite current challenges.","metaDescription":"Regeneron Pharmaceuticals (REGN) Q4 2010 earnings: EPS missed. Stock down 0.08%. Full breakdown."}}